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Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion
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ABSTRACT
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases
(PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on
the potential to adequately treat small, poorly vascularized PM. Despite a history of more than three
decades, many aspects of IP drug delivery remain poorly studied.
Areas covered: We outline the anatomy and physiology of the peritoneal cavity, including the pharmaco-
kinetics of IP drug delivery. We discuss transport mechanisms governing tissue penetration of IP chemother-
apy, and how these are affected by the biomechanical properties of the tumor stroma. We provide an
overview of the current clinical evidence on IP chemotherapy in ovarian, colorectal, and gastric cancer. We
discuss the current limitations of IP drug delivery and propose several potential areas of progress.
Expert opinion: The potential of IP drug delivery is hampered by off-label use of drugs developed for
systemic therapy. The efficacy of IP chemotherapy for PM depends on cancer type, disease extent, and
mode of drug delivery. Results from ongoing randomized trials will allow to better delineate the
potential of IP chemotherapy. Promising approaches include IP aerosol therapy, prolonged delivery
platforms such as gels or biomaterials, and the use of nanomedicine.
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Anticancer drugs are usually administered systemically, resulting
in exposure of healthy tissue, which limits their therapeutic
index. Locoregional drug delivery, targeted at the tissue or
organ of interest, may allow to increase treatment intensity
while at the same time limiting systemic toxicity. Over the past
decades, several methods of locoregional anticancer therapy
have been clinically implemented. These include instillation in
an anatomical cavity (intraperitoneal, intravesical, intrathecal,
intrapleural) or selective infusion into a feeding artery with or
without vascular isolation of the target organ. In parallel, inno-
vative pharmaceutical platforms such as targeted agents, nano-
sized medicine and drug eluting beads have the potential to
further increase the appeal of locoregional drug delivery.
The peritoneal cavity, with its serosal exchange surface of
approximately 1.5–2 square meters, is a well-established route
of drug delivery [1]. Examples include renal replacement using
peritoneal dialysis and intraperitoneal instillation of analgesic
compounds following laparoscopic surgery [2,3]. Recently,
there has been an increase in interest from clinicians in intra-
peritoneal (IP) instillation of anticancer drugs for abdominal
malignancy. The concept of IP therapy is not entirely new. The
earliest IP ‘drug therapy’ was reported in 1744 by the English
surgeon Christopher Warrick, who, apparently with great suc-
cess, injected a mixture of ‘Bristol water’ and ‘claret’ (a
Bordeaux wine) in the peritoneal cavity of a woman suffering
from intractable ascites [4]. In the 1940 s, interest arose in
intraperitoneal administration of radionuclides. Intraperitoneal
colloidal radioactive gold (Au-198) was used as adjuvant treat-
ment or as palliation of ascites and pleural effusions in ovarian
cancer patients. Although some success was reported, serious
complications and deaths were also observed [5]. Similarly,
adjuvant IP instillation of radioactive chromic phosphate (32P)
was associated in early stage ovarian cancer with inadequate
distribution and small bowel perforation [6]. In 1958,
Economou and coworkers reported the use of intra-operative
IP delivery of nitrogen mustard (HN2, bis(2-chloroethyl)methy-
lamine, mustine) in 36 patients undergoing laparotomy for
cancer, and concluded this to be a ‘safe’ procedure [7]. The
interest in IP chemotherapy was encouraged by the work of
Robert Dedrick in the nineteen seventies, who proposed
a theoretical framework for IP therapy based on the assump-
tion that, since peritoneal clearance is much lower than
plasma clearance, a regional pharmacokinetic (PK) advantage
results in much higher IP drug concentrations with limited
systemic exposure and toxicity [8]. The same author, however,
was also one of the first to highlight the fact that, despite the
PK advantage of IP instilled chemotherapy, tissue penetration
depth remains very limited [9].
Hyperthermic intraperitoneal chemoperfusion (HIPEC) was
first described in an animal model in 1974 by Euler [10]. The
first clinical application of combined cytoreduction and HIPEC
was reported in 1980 by Spratt and coworkers, who reported
HIPEC with Thiotepa [11]. The authors stressed the importance
of removing free floating cancer cells by the microfilters in the
perfusion circuit. The advantage of intraoperative (as opposed
to adjuvant) chemoperfusion is the possibility to achieve
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optimal chemotherapy exposure of all peritoneal surfaces at
risk. The use of hyperthermia is based on several observations.
First, hyperthermia is selectively cytotoxic for malignant cells
[12]. Second, the cytotoxicity of several chemotherapeutic
agents such as the platinum compounds and the alkylating
drugs is enhanced by hyperthermia [13]. Third, hyperthermia
enhances tissue perfusion and oxygenation, and may improve
drug penetration. Los and coworkers demonstrated
a significant increase in peritoneal tumor platinum concentra-
tions when IP cisplatin therapy was combined with regional
hyperthermia (41.5°C) in a rat colon cancer model [14]. Other
drugs that were shown to exhibit increased tumor penetration
under hyperthermic conditions are carboplatin, oxaliplatin,
and doxorubicin [15,16].
Here, we aimed to outline the anatomy and physiology of the
peritoneal cavity, to highlight the pharmacokinetics of IP drug
delivery and the importance of the tumor stroma, and to provide
an overview of current clinical evidence, existing challenges, and
promising novel approaches related to IP chemotherapy.
2. Structure and transport barrier function of the
peritoneum
The peritoneal cavity contains a small volume (approx.
10–100 mL in physiological conditions) of peritoneal fluid
(PF), which contains growth factors, nutrients, cytokines, and
chemokines as well as leukocytes, all of which are continu-
ously exchanged between the PF and the blood [17]. The
peritoneal fluid moves in a cephalad direction due to the
movement of the diaphragm which creates a relatively low
pressure zone in the upper abdomen [18]. The peritoneum
that covers the diaphragm is characterized by lymphatic ‘sto-
mata’, cavities with a diameter of 3–12 µm between the
mesothelial cells [19]. These stomata provide direct access to
an underlying network of lymphatic vessels, lacunae, and
cisternae which allow to clear particulate matter, bacteria,
and cells from the peritoneal cavity into the circulation
[20,21]. Recent cadaveric research showed that the mean
peritoneal surface area in the adult female is approximately
1.43 m2, with the small bowel and its mesentery accounting
for 39% of the total surface [1].
The interior aspect of the abdominal wall and the viscera are
covered by a peritoneal layer consisting of mesothelial cells
(MCs), which are flat, squamous like cells approximately 25 µm
in diameter, and by an underlying extracellular matrix (ECM)
[22]. The mesothelial cells provide a protective, non-adhesive
surface by production of surfactant, proteoglycans, and glyco-
saminoglycans. Also, they have a role in transport of fluid and
cells across the peritoneal cavity, present antigens to T cells, and
participate in inflammation and tissue repair by the secretion of
chemokines (MCP-1 and IL-8), cytokines (IL-6 and IL-1), growth
factors (TGF-beta, FGF, PDGF), ECM components, and other
biological mediators [23]. Mesothelial cells display pattern-
recognition receptors, such as Toll-like receptors, RIG-I–like
receptors, and C-type lectin-like receptors, which recognize
microbial pathogens and stimulate release of inflammatory
mediators and activation of immune pathways [22].
The structural and functional features of MCs differ according
to anatomical location. Flat MCs cover the abdominal wall and
omentum, and are characterized by a poor organelle apparatus,
less microvilli, and a slower metabolism [24]. The omentum,
which consists of loose tissue with a high concentration of
adipocytes and milky spots, is known to be frequently involved
in patients with peritoneal metastasis. In ovarian cancer, omental
adipocytes were shown to promote peritoneal metastasis forma-
tion by providing growth signals and an energy source [25]. Also,
the omental metastatic cascade involves the influx of neutro-
phils, which extrude neutrophil extracellular traps (NETs), a web-
like structure of chromatin which may mechanically ‘trap’ cancer
cells [26]. Cuboidal MCs have well developed organelles, elec-
tron-dense granules, a rich vesicular system, and numerous and
longer microvilli [27]. They cover organs with a reservoir function
(stomach, rectum, urinary bladder, uterus), the spleen, and ovar-
ies. Also, cuboidal MCs form the highly specialized regions
around the lymphatic stomata.
Functionally, the mesothelial lining does not represent
a significant barrier to drug transport, as demonstrated by pre-
clinical and clinical studies showing that peritonectomy does not
affect transport characteristics of IP chemotherapy [28]. The trans-
port barrier consists of the submesothelial stroma and, impor-
tantly, the endothelial glycocalyx lining the submesothelial
capillaries [29].
3. Pharmacokinetics and tissue transport after IP
chemotherapy
3.1. Background
The PK rationale for IP cytotoxic drug administration was first
proposed by Dedrick et al. in 1978 and is based mainly on the
peritoneal-plasma barrier [30]. The presence of this barrier results
in a peritoneal drug clearance that ismuch slower than the plasma
clearance. The PK advantage associatedwith IP administrationwas
expressed by Dedrick as the parameter Rd, calculated as (CP
/CB)IP/(CP/CB)IV with CP and CB the peritoneal and blood concen-
trations, respectively [31]. Theoretically, the regional advantage
will be inversely proportional to the peritoneal clearance and
proportional to the plasma clearance. The PK behavior of IP admi-
nistered drug is usually expressed as ratio of the area under the
concentration versus time curve (AUC) in peritoneal perfusate
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versus plasma. The kinetic behavior of IP chemotherapy is usually
described using a compartmental model, consisting of a systemic
and a peritoneal compartment. Both compartments are separated
by the peritoneal barrier, characterized by a permeability-area (PA)
product. The PA product of the peritoneal barrier cannot be
directly measured. However, from correlations of drug clearance
with molecular properties, it was estimated that the PA decreases
approximately with the square root of the molecular weight [9].
3.2. Convection vs. diffusive transport
While IP drug delivery results in a PK advantage, its anticancer
efficacy is determined not by the presence of peritoneal drug,
but by tumor tissue concentrations [32,33]. Therefore, adequate
tissue transport is of paramount importance (Figure 1). The
physiological study of drug transport usually considers tumor
tissue as an isotropic (homogeneous) porous medium [34].
Interstitial mass transport is driven by two main mechanisms:
convection or bulk fluid flow, driven by a pressure gradient, and
diffusion, which results from a concentration gradient.
The ratio of convective versus diffusive transport is defined
as the dimensionless Péclet number. The Péclet number is low
for small molecules (transport mainly diffusion driven) and
higher for larger substances such as antibodies or nucleic
acids (transport mainly driven by convection).
Convection describes the interstitial fluid flow resulting from
a pressure gradient. Since tumor tissue is characterized by an ele-
vated interstitial fluid pressure (IFP), which decreases sharply at the
tumor periphery, an net outward convective flow results in ‘oozing’
from the tumor surface [35]. Interstitial fluid pressure ranges from
4–100 mm Hg, and this has to be balanced against the pressure
exerted by the intraperitoneal fluid column (average of 10–20 cmH2
O or 7.4–14.8 mm Hg) when IP chemotherapy is instilled.
Solid tissue stress in tumors arises from three different
sources [36]. External solid tissue stress is exerted on the
tumor as it grows in and compresses the surrounding tissue.
Swelling solid tissue stress, on the other hand, results from
electrostatic repulsive forces between negatively charged stro-
mal components (hyaluronic acid), and from adaptive changes
in cancer cell tonicity [37]. A third source of stress is residual
solid tissue stress, which represents stored elastic energy and
can be estimated by making cuts in the tissue leading to
measurable bulging and deformation. Interestingly, stromal
stiffness and tumor solid stress are not necessarily related.
Nia et al. measured both parameters in a mouse CRC model
and found a significantly higher solid stress in liver metastatic
compared to primary tumors, while the elastic modulus did
not differ between both [38].
The degree of convective drug transport depends on the
hydraulic conductivity of the tissue, which is determined by
the viscosity of the interstitial fluid and by the stromal archi-
tecture or mechanical ‘stiffness’ [39]. Since chemotherapy will
interact with cellular and stromal structures, solute transport
velocity is always slower than fluid velocity. The ratio of both
velocities is termed the retardation or hindrance coefficient.
The rate of drug diffusion is proportional to a concentration
gradient, according to Fick’s first law of diffusion. The rate of
diffusion depends on temperature, the physicochemical drug
properties, and on the stromal architecture [40]. The tempera-
ture dependence is explained by the Einstein-Stokes equation,
which states that diffusion is proportional to temperature and
inversely proportional to the viscosity of the medium. The
extent of diffusive transport depends on properties of the
drug (molecular weight, size, charge, configuration) and the
extracellular matrix (cellular composition, density, visco-
elasticity, geometrical arrangement, electrostatic properties)
[41]. Since the shape of a molecule will affect its diffusive
behavior more than its molecular weight, the Stokes-Einstein
radius of a molecule is often used as a measure of its size.
3.3. Tumor stroma
Tumor stroma mainly consists of adipose tissue, smooth mus-
cle, and epithelial cells, but also includes pericytes, endothelial
Figure 1. Overview of drug, perfusate, and tissue properties that determine tissue penetration after intraperitoneal drug delivery (IPDD).
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cells, leukocytes, and activated fibroblasts (cancer-associated
fibroblasts or CAFs) [42,43].
Cancer associated fibroblasts play a central role in remodel-
ing the malignant stroma. They produce a vast array of extra-
cellular matrix molecules, chemokines, cytokines and growth
factors, which fuel malignant progression and accelerate
metastasis formation [44].
Interestingly, due to intense reciprocal interaction with the
tumor microenvironment, stromal cells develop a modified
phenotype and altered function [42]. Tumor tissue is charac-
terized by increased deposition of collagen I, the most abun-
dant extracellular matrix (ECM) protein. As a result, tumor
stroma is characterized by increased stiffness or rigidity com-
pared to normal tissue. Rigidity (or stiffness) is measured using
Young’s modulus of elasticity, which is the ratio of stress to
strain along an axis. Tissue elasticity can be measured using
a mechanical device that directly applies a mechanical load
and measures the resulting deformation. Alternatively, nonin-
vasive elastography techniques can be used with ultrasound
or magnetic resonance imaging (MRI) [45,46]. In addition to
increased collagen deposition, tumors were shown to further
exacerbate matrix stiffness by increased expression of the
collagen cross linking enzyme LOX (lysyl oxidase) [47]. Paszek
and coworkers found that tissue stiffness of mouse mammary
tumors far exceeded that of normal breast tissue (elastic mod-
ulus 4049 ± 938 Pa versus 167 ± 31 Pa) while mechanical
disturbances were shown to enhance the malignant pheno-
type through ‘mechanoregulatory’ circuits [48,49].
In addition to the density of the collagen fibers that are
deposited in the ECM, their geometric arrangement may affect
drug diffusion. Fibers that are oriented tangentially from the
tumor surface may direct drug diffusion away from the tumor,
while the oppositemay result from fibers that are radially aligned
[50]. In addition to stromal components, the tumor cell popula-
tion in itself represents a barrier to diffusive drug transport. Using
advanced imaging techniques, Chauhan and coworkers demon-
strated a significant improvement of macromolecular diffusion
when colorectal xenografts were treated with diphtheria toxin,
which causes apoptosis of tumor cells but leaves the mouse
stroma intact [51]. Other cell types include fibroblasts, myofibro-
blasts, mesenchymal cells such as pericytes, endothelial cells, and
immune cells, all of which contribute to a high cellular density
and solid stress, compressing the interstitial matrix. Drug pene-
tration following intraperitoneal drug delivery (IPDD) is limited to
a few millimeters, and depends on numerous drug, treatment,
and tissue related variables [52]. Numerous physical, chemical,
and pharmacological approaches have been tested preclinically
in order to enhance drug penetration after IPDD [33].
In patients with extensive mucin production such as those
with the pseudomyxoma peritonei syndrome or mucinous
adenocarcinoma of the colon, the presence of IP mucus repre-
sents an additional barrier to chemotherapy transport [53].
Several approaches to enhance penetration of mucus barriers
have been proposed, including mucoadhesive and mucus-
penetrating drug carriers [53]. Interestingly, Morris and cow-
orkers developed an approach consisting of intraperitoneal
instillation of the pineapple-derived enzyme bromelain and
acetylcysteine to achieve dissolution of tumor-produced
mucin in patients with peritoneal mucinous tumors [54].
4. Current clinical implementation of intraperitoneal
drug delivery
Intraperitoneal chemotherapy is currently administered using
two different approaches. The first one is neoadjuvant (pre-
operative) or adjuvant (postoperative) cycles of IP chemother-
apy using an indwelling Tenckhoff type catheter [55].
The second approach is HIPEC, during which the peritoneal
cavity is perfused immediately after cytoreductive surgery
(CRS) using a closed or open (coliseum) abdomen approach
[56]. Some centers add early postoperative, IP catheter based
chemotherapy to HIPEC during a period of 5 days [57].
A recent development in patients with unresectable peritoneal
metastases is pressurized intraperitoneal aerosol chemother-
apy or PIPAC (Figure 2). This novel concept of intraperitoneal
drug delivery combines a diagnostic laparoscopy with locor-
egional administration of chemotherapy as an aerosol, which
is generated by a patented nebulizer [58].
Several advantages are associated with the addition of
PIPAC to the therapeutic strategy in patients with irresectable
PM. First, locoregional (IP) chemotherapy delivery allows to
intensify exposure of peritoneal metastases, which are known
to be poorly vascularized, while systemic absorption and side
effects remain limited. Second, compared to liquid instillation,
the physical properties of the aerosol combined with the
established capnoperitoneum (peritoneal cavity filled with
CO2 gas to a pressure of 12 mm Hg) allows better spatial
distribution throughout the peritoneal cavity, and results in
improved tissue penetration [58]. A recent experimental study
in pigs compared PIPAC with HIPEC using oxaliplatin, and
found that peritoneal drug concentrations were significantly
higher in the visceral peritoneum in the PIPAC group [60].
Third, unlikemajor surgical debulking, laparoscopy and PIPAC
can be repeated (usually every 4–6 weeks). This offers the poten-
tial not only to enhance anticancer efficacy, but also to ade-
quately stage the extent of peritoneal metastastases (PM) and
to verify histological response on biopsies, both of which are
virtually impossible using the current, standard systemic che-
motherapy approaches. The concept of PIPAC has evolved
from innovation to technological maturity (phase 2B of the
IDEAL framework) [61]. A recent review of results from retro-
spective studies obtained by early adopters confirmed the safety
of the concept, and a promising response rate in PM
patients [62].
A major drawback of IPDD is the fact that none of the cur-
rently used drugs were developed or approved for intraperito-
neal instillation. Therefore, clinical practice is limited to off-label
use. The most commonly used chemotherapy drugs for IP use
are the platinum compounds (cisplatin, carboplatin, oxaliplatin),
mitomycin C, and paclitaxel. Intraperitoneal immune therapy has
as yet found only a very limited clinical application. The trifunc-
tional antibody Catumaxomab contains binding sites for EpCAM
and CD3+T cells, while the Fc domain binds to type I, IIa, and III
Fcγ receptors on DCs, NKs, and macrophages. The molecule was
approved by the European Medicines Agency for palliation of
ascites in EpCAM positive epithelial cancers. Analysis of clinical
ascites samples showed that treatment with IP Catumaxomab
enhances the expression of the activation molecules CD69 and
CD38 in T cells, NK cells, and macrophages, while accumulation
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of CD8+T cells into the peritoneal cavity was enhanced [63]. Also,
IP Catumaxomab was shown to promote recruitment of inflam-
matory TH1 cells (capable of degranulating and secreting IFN-γ)
and to stimulate expression of TRAIL by NK cells, and costimula-
tory molecules by monocytes [64]. However, due to its high
immunogenicity rate and narrow indications, commercial sale
of Catumaxomab was discontinued in 2017. A comparable
approach was reported by Froysnes et al., who successfully
treated colorectal PM patients with IP MOC31PE immunotoxin,
consisting of an antibody recognizing EpCAM conjugated to the
potent Pseudomonas exotoxin A [65].
5. Clinical results of intraperitoneal chemotherapy
5.1. Ovarian cancer
Themajority of epithelial ovarian cancer (EOC) patients presents
with stage III disease, and around 75%will develop platinum (Pt)
resistance and relapse in the peritoneal cavity after successful
first line treatment. The mechanisms leading to Pt resistance
include increased drug efflux (e.g. by changes in the expression
of the copper transporter CTR-1), changes in intracellular Pt
binding proteins, and altered expression of pro-survival and
anti-survival proteins [66]. Since the disease is (initially) confined
to the peritoneal cavity in most patients, EOC remains the best
studied indication for IP chemotherapy. Four large randomized
trials have studied adjuvant IP chemotherapy following optimal
primary CRS (Table 1). Three of these trials demonstrated
a consistent and clinically meaningful improvement of progres-
sion free and overall survival, leading to the January 2006
announcement of the US National Cancer Institute recommend-
ing that ‘strong consideration should be given’ to a regimen
containing IP cisplatin and a taxane following optimal cytore-
duction in women with stage III ovarian cancer [67]. However,
the GOG 252 trial, which randomized patients in three arms
including an IP cisplatin and an IP carboplatin arm, all three
with bevacizumab, failed to show a difference in either progres-
sion free survival (PFS) or overall survival (OS) (Table 1) [68]. Why
this trial did not confirm the findings of earlier trials is not clear,
but this may relate to a lower dose of IP cisplatin, the addition of
bevacizumab, and a shorter infusion duration of paclitaxel,
known to potentially act as a ‘primer’, which enhances IP drug
penetration by reducing cellular density [69]. The OV21/PETROC
trial studied the addition of IP chemotherapy with carboplatin
after interval CRS [70]. Despite early closure due to funding
issues, the investigators found that the addition of IP carbopla-
tin resulted in significantly improved 9-month progressive dis-
ease rate.
A systematic review of the available early phase data on the
use of HIPEC in EOC suggested promising overall survival
outcomes (range: 22–54 months) whilst the associated mor-
bidity and mortality (5% – 36% and 3% respectively) were in
keeping with that of other major abdominal procedures [74].
The recently published OVHIPEC trial demonstrated that the
addition of HIPEC with cisplatin to interval CRS resulted in
a significantly better progression free and overall survival
[75]. A second smaller trial, published as abstract only, used
a lower IP cisplatin dose, included both primary and interval
CRS cases, and did not find a difference in PFS [76]. A French
multicenter randomized trial (CHIPOR; ClinicalTrials.gov identi-
fier: NCT01376752) was initiated in 2011 comparing cytore-
duction alone with cytoreduction plus HIPEC in recurrent
ovarian cancer.
Nevertheless, IP chemotherapy for ovarian cancer remains
a matter of debate for a number of reasons [77]. First, technical
problems and locoregional toxicity may limit the applicability of
locoregional drug therapy. Second, optimal cytoreduction often
entails colorectal procedures and many clinicians will hesitate to
implant an IP delivery system in this circumstance. Finally, the
randomized trials used heterogeneous IV and IP regimens, and
Figure 2. Pressurized intraperitoneal aerosol chemotherapy (PIPAC). The abdominal cavity is accessed with 2 balloon trocars allowing hermetic seal. Liquid
chemotherapy is dispersed as an aerosol by use of a high pressure injector and a specific nebulizer. Reprinted with permission from from Rev Med Suisse. [59].
EXPERT OPINION ON DRUG DELIVERY 5
some of the control arms included IV regimens that were no
longer considered standard of care at the time of analysis.
5.2. Colorectal cancer and appendiceal neoplasms
Approximately one in five colorectal cancer patients harbors
peritoneal minimal residual disease (MRD) after surgical resec-
tion while peritoneal carcinomatosis develops in about 15% of
patients [78]. Therefore, a strong theoretical rationale exists for
IP chemotherapy following complete resection of locally
advanced (T3N+or T4) colorectal cancer (CRC).
In animal models of CRC, intra peritoneal administration of
chemotherapy successfully prevented tumor development fol-
lowing IP injection of cancer cells [79]. Several authors have
studied adjuvant IP chemotherapy following surgery in an
effort to reduce the risk of peritoneal recurrence. A small
clinical study was reported by Sugarbaker and coworkers,
who assigned 66 patients to receive either intravenous (IV)
or IP 5-FU [80]. Although no difference in disease free or
overall survival (OS) was noted, the risk of peritoneal
recurrence was significantly lower in the patients who under-
went IP therapy (91% versus 20%, P < 0.0001). Similar results
were obtained by Scheithauer et al., who randomized 241
patients with resected stage III or T4N0M0 CRC to either IV
5-FU and levamisole, or combined IV and IP 5-FU and leucov-
orin [81]. A significant improvement in DFS and OS was noted
in stage III, but not in stage II patients. Compared with the IV
alone group, patients who received combined IV and IP adju-
vant therapy had a significantly lower risk of locoregional
recurrence (21% versus 7.6%, P = 0.005). Two other trials
were unable to demonstrate a benefit of IP chemotherapy in
CRC. Vaillant and coworkers randomly allocated 267 stage II
and III CRC patients to either surgery alone or surgery com-
bined with intraoperative IV 5-FU and early postoperative IP
5-FU during six days [82]. Overall, the experimental therapy
failed to improve DFS, OS, or the risk of peritoneal recurrence.
An unplanned subgroup analysis suggested a DFS benefit in
patients with stage II disease. Similarly, the randomized trial by
Nordlinger et al. failed to show any survival benefit of immedi-
ate postoperative regional chemotherapy (IP or intraportal
Nanoparticles
+ Surface modification with tumor targeting ligands
+ Decreased off-target toxicity
-  Rapid peritoneal clearance
-  Potential instability in biological fluids
Microparticles
+ Prolonged intraperitoneal residence time
-  Risk of peritoneal adhesions
Hydrogels
+ Controlled drug release
+ Prevention of peritoneal adhesions
-  Increased viscosity hampers injection
Implantable matrices and nanotextiles
+ Decreased off-target toxicity
-  Surgical implantation
peritoneal membrane peritoneal membrane
peritoneal membraneperitoneal membrane
peritoneal cavity peritoneal cavity
peritoneal cavityperitoneal cavity
tumor cells tumor cells
tumor cells
tumor cells
Figure 3. Overview of novel delivery platforms and carriers for intraperitoneal drug delivery.
6 W. CEELEN ET AL.
5-FU according to treatment center) followed by IV 5-FU based
chemotherapy compared with IV chemotherapy alone in
patients with resected stage II or III CRC [83]. No data on
locoregional recurrence were reported from this trial.
A Swedish study randomized patients between surgery and
adjuvant IP 5-FU, or systemic chemotherapy (FOLFOX) alone,
both during 6 months [84]. The trial closed prematurely due to
poor accrual, but showed a significantly better OS, but not
PFS, in the surgery/IP chemotherapy arm.
The role of HIPEC in PM from CRC is currently debated. The
landmark trial by Verwaal and coauthors compared systemic
5FU/leucovorin and palliative surgery, when required, with
extensive cytoreduction and HIPEC using mitomycin
C (35 mg/m2) followed by the same chemotherapy in patients
with PC from CRC [85,86]. The median disease specific survival
was 12.6 months in the control arm and 22.2 months in the
cytoreduction with HIPEC arm (P = 0.028); survival was signifi-
cantly better in patients with no more than five of seven
abdominal regions affected and in patients in whom
a macroscopically complete resection was achieved. The sig-
nificance of that trial is limited by the use of outdated sys-
temic chemotherapy, and by its inability to discriminate the
effects of surgery alone versus the addition of HIPEC. A similar
study by the US National Cancer Institute (NCT01167725)
compared best systemic treatment with versus without CRS/
HIPEC but was closed due to poor accrual.
A recent French multicentre study compared CRS alone with
CRS combined with oxaliplatin based HIPEC in colorectal PM
(Prodige 7/ACCORD 15, NCT00769405) [87]. Disappointingly,
HIPEC did not improve OS, but did increase 90 day morbidity.
The role of ‘prophylactic’ HIPEC with oxaliplatin was evaluated in
patients at high risk of peritoneal recurrence (i.e., perforated
tumors, pT4 tumors, minimal PM resected at the time of primary
surgery, and ovarian (Krukenberg) metastases). However, both
the French ProphyloChip (NCT01226394) and a similar Dutch
study by Klaver et al were negative [55,88,89]. Final results from
the French trials, published as abstract only, are awaited.
However, they do raise questions on the efficacy of IP oxaliplatin
[90]. A similar randomized study of ‘prophylactic’ HIPEC pro-
posed by the National Cancer Institute (NCT01095523) has
been withdrawn [91].
Appendiceal mucinous neoplasms represent a rare, histo-
logically heterogeneous entity encompassing mucinous ade-
noma, mucinous neoplasms with uncertain or low malignant
potential, and mucinous carcinoma [92–94]. When ruptured,
low grade tumors may cause accumulation of mucinous
ascites, giving rise to the ‘pseudomyxoma peritonei’ (PMP)
syndrome, a clinical or radiological descriptor rather than
a histopathological diagnosis [95]. Impressive long term survi-
val results have been achieved in patients with PMP using CRS
and HIPEC [96–98]. Results from a recent international registry
including over 2000 patients showed a median survival of
16.3 years and a 10 year survival of 63% following cytoreduc-
tive surgery and HIPEC for PMP [99]. Therefore, this approach
has been proposed as the standard of care in patients with
low grade appendiceal tumors associated with PMP [100].
Others have argued that the outcome achieved in these
patients is mainly resulting from a favorable tumor biology
Table 1. Randomized trials of platinum based IP chemotherapy in women with stage III epithelial ovarian cancer.
Therapy PFS OS
Author N IV IP Median HR Median HR
CRS followed by IP chemotherapy
Alberts[71] 267 Cyclophosphamide 600 mg/m2 Cisplatin 100 mg/m2 49 0.61–0.96
SWOG 8501/GOG 104
279 Cyclophosphamide 600 mg/m2 41
Cisplatin 100 mg/m2
Markman[72] 235 Carboplatin AUC 9 Cisplatin 100 mg/m2 27.9 0.66–0.94 63.2 0.65–1
227 Paclitaxel 135 mg/m2 22.2 52.2
Cisplatin 75 mg/m2
Armstrong[73] 205 Paclitaxel 135 mg/m2 Cisplatin 100 mg/m2 23.8 0.64-1 65.6 0.58–0.97
GOG 172 Paclitaxel 60 mg/m2 Paclitaxel 60 mg/m2
210 Paclitaxel 135 mg/m2 18.3 49.7
Walker[68] 521 Paclitaxel 80 mg/m2 24.9 75.5
GOG 252 Carboplatin AUC 6
Bevacizumab 15 mg/kg
518 Paclitaxel 80 mg/m2 Carboplatin AUC 6 27.4 0.8–1.07 78.9 0.8–1.13
521 Paclitaxel 135/60 mg/m2 Cisplatin 75 mg/m2 26.2 0.85–1.13 72.9 0.88–1.24
Bevacizumab 15 mg/kg
NACT followed by interval CRS and IP chemotherapy
Provencher[70] 101 Paclitaxel 135 mg/m2 11.3 NA
OV21/PETROC Carboplatin AUC 5/6
72* Paclitaxel 135 mg/m2 Cisplatin 75 mg/m2
Paclitaxel 60 mg/m2
102 Paclitaxel 135 mg/m2 Carboplatin AUC 5/6 12.5 0.57–1.17 NA
NACT followed by interval CRS and HIPEC
Van Driel[75] 110 CRS alone 10.7 33.9
123 CRS HIPEC (Cisplatin 100 mg/m2) 14.2 0.5–0.87 45.7 0.48–0.94
Lim[76] 92 CRS alone 5yPFS: 16% 5yOS: 49.4%
92 CRS HIPEC (cisplatin 75 mg/m2) 5yPFS: 20.9% 5yOS: 51%
CRS, Cytoreductive surgery; HIPEC, Hyperthermic intraperitoneal chemoperfusion; NA, not available; IV, intravenous; IP, intraperitoneal; PFS, progression free survival
(months); OS, overall survival (months); HR, hazard ratio of the control versus the experimental IP arm (95% confidence interval); SWOG, Southwest Oncology
Group; GOG, Gynecologic Oncology Group; AUC, area under the concentration versus time curve. *treatent arm discontinued after planned interim analysis; 5yPFS,
five year progression free survival; 5yOS, five year overall survival.
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and that, given the proven prognostic impact of complete
surgical cytoreduction, the contribution of IP chemoperfusion
remains uncertain [101]. There are no randomized trials avail-
able that have compared CRS and HIPEC with surgery alone in
PMP patients.
5.3. Gastric cancer
The risk of peritoneal metastasis in gastric cancer is approxi-
mately 15% [102,103]. In the Far East (primarily Japan), promising
results have been obtained with prolonged IP taxane based
chemotherapy in gastric cancer patients with PM [104,105].
Meta-analyses of small RCT’s and non-controlled trials sug-
gest a potential benefit of HIPEC in gastric cancer, specifically
in patients with positive cytology and without extensive nodal
disease [106,107]. A recent propensity score adjusted compar-
ison of CRS alone versus CRS with HIPEC in gastric cancer with
PM suggested that the addition of HIPEC results in
a significant improvement of both recurrence free and overall
survival [107]. Randomized trials are currently exploring the
efficacy of HIPEC in gastric cancer with PM in the Netherlands
(PERISCOPE II, NCT03348150), France (GASTRICHIP,
NCT01882933), and China (NCT02356276)
5.4. Other intra-abdominal cancers
Promising results have been obtained using CRS and HIPEC in
patients with malignant peritoneal mesothelioma, a condition
for which very few other effective therapy options are available.
A systematic review of six published series totaling 240 patients
showed a median survival ranging from 34 to 92 months [108].
Other peritoneal cancers that were treated with IP che-
motherapy in small numbers of patients include small bowel
adenocarcinoma, sarcomas, and desmoplastic small round cell
tumors [109,110].
6. Novel intraperitoneal drug delivery platforms
One of the reasons for failure of IP drug delivery is the limited
residence time of chemotherapeutic solutions typically admi-
nistered during HIPEC or PIPAC procedures. Innovative drug
delivery systems which control the release of their cargo can
prolong the exposure time of drugs to the tumor site and
therefore enhance therapeutic efficacy (Figure 3). One exam-
ple of such a delivery platform is the application of nanome-
dicines, defined as nanoparticles (NPs) with a diameter
between 1 and 1000 nm used as carriers to deliver drugs
and biopharmaceuticals [111].
Advantages of nanomedicines in cancer therapy include an
improved drug protection and solubility, decreased off-target
toxicity, controlled release and the potential to modify their
surface with tumor targeting ligands which can lead to an
enhanced tumor accumulation and retention [112].
Nanoparticles under (clinical) investigation to treat peritoneal
metastases can carry conventional cytostatic agents such as
paclitaxel and doxorubicin [113–116]. Examples of clinically
approved nanoformulations that are being tested for intraper-
itoneal application include nanoparticle albumin bound pacli-
taxel (nab-paclitaxel, Abraxane™) and liposomal doxorubicin
(Caelyx™) [113,117]. On the other hand, nanotherapeutics can
be used to deliver nucleic acids such as plasmid DNA (pDNA)
aimed at inducing the expression of certain proteins and small
interfering RNA (siRNA) intended to downregulate targeted
protein expression [118]. An important aspect regarding the
IP delivery of nanomedicines is the colloidal stability of these
therapeutics in the presence of biological fluids encountered
in the IP cavity, e.g., ascites fluid. NPs in contact with these
biofluids should remain intact and show resistance against
aggregation, premature release of cargo, loss of targeting
potential and reduced cellular uptake [111]. This also applies
to the IP delivery of NPs using pressurized aerosolization
(PIPAC) as administration method in the sense that these
nanomedicine formulations should withstand high shear
forces during nebulization [112,119].
It is generally accepted that nano-sized drug delivery car-
riers are rapidly cleared from the peritoneal cavity through
drainage via micron-sized lymphatic duct openings. To cir-
cumvent this size-dependent phenomenon, microparticulate
formulations (>1 µm) are explored with the aim to obtain
a prolonged release of encapsulated drugs [120]. However,
applying these systems intraperitoneally can induce peritoneal
inflammation and adhesions on a long-term basis
[112,121,122]. Often the size of these particles is designated
as the prime contributing factor to this hazard. This should
nevertheless be nuanced as microspheres already have been
developed to prevent peritoneal adhesions which suggests
the risk for inflammation and adhesions also depends on
other factors than size e.g. molecular weight and degradation
rate of polymeric building blocks together with the prolonged
IP residence time of microspheres [122,123].
Another way of increasing the exposure time of IP adminis-
tered drugs to tumor tissue is to incorporate them in injectable
hydrogels, also described as macroscopic, three-dimensional,
cross-linked networks of water-soluble polymers. The encapsula-
tion of naked lowmolecular weight drugs in hydrogels often fails
to extend release times compared to aqueous drug solutions
since these gels host large quantities of water and possess
relatively large pore sizes. This justifies the development of
hydrogel formulations where drug loaded nano- or microparti-
cles are entrapped in the entangled polymer network [120,121].
Beside their potential to control drug release, hydrogels have the
additional benefit of preventing postsurgical peritoneal adhe-
sion formation. To overcome injection related difficulties caused
by the increased viscosity of gels, thermosensitive hydrogels
offer a convenient solution. These formulations behave as
a liquid at room temperature while forming a non-flowing gel
at body temperature [124]. Finally, implantable sustained release
matrices and nanotextiles have been described for the IP treat-
ment of metastatic ovarian cancer. These systems show encoura-
ging results regarding therapeutic efficacy and safety, but
require surgical proficiency to enable implantation [124,125].
7. Conclusion
There are compelling theoretical arguments for the incorpora-
tion of IP chemotherapy in a multimodal strategy for the treat-
ment of PM. Its current place is, however, uncertain due to the
lack of drugs and platforms that are developed specifically for IP,
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and to the significant variability in the methods used to admin-
ister IP drugs. Successful further implementation of IP che-
motherapy will require a better basic understanding of how IP
therapy affects the peritoneal ecosystem, development of novel
IP compounds and delivery systems, and expansion of the clin-
ical evidence base from randomized trials.
8. Expert opinion
Intraperitoneal chemotherapy has been increasingly used for at
least three decades. However, its efficacy has come under scru-
tiny after the publication of disappointing results from rando-
mized trials in both ovarian (GOG 252) and colorectal
(PRODIGE 7) peritoneal metastases. Several circumstances should
be taken into account. First, none of the drugs currently used for
IP chemotherapy were developed for that route of administra-
tion. Drugs such as oxaliplatin or mitomycin C are vesicant or
irritant agents, and the potential damage they cause to the
mesothelial integrity and the host defense of the peritoneal
ecosystem are probably underestimated, and certainly insuffi-
ciently studied. Oxaliplatin has been observed to potentially
cause severe peritoneal sclerosis after IP administration [126].
Similarly, carrier solutions such as dextrose 5% or ‘normal’ saline
may disturb tissue homeostasis due to their acid pH and the
production of advanced glycation end products.90 Second, in
contrast to intravesical or intrathecal administration, IP che-
motherapy is confronted with the anatomical challenges posed
by peritoneal cavity, which is far from homogeneous or uniform
and access to which is often impeded by surgical adhesions. As
a result, single branched catheters often fail to adequately reach
all the peritoneal surfaces at risk. Also, the requirement to fill and
distend the abdomen and to implant foreign material puts
patients at risk for side-effects such as pain, infection, and
obstruction. Third, HIPEC was clinically introduced two decades
ago without a solid basis in preclinical or translational science. It
is likely, for example, that a single 30 minutes chemotherapy
perfusion is inadequate to efficiently treat the entire tumor cell
population, and even more so when using cell cycle specific
agents such as the taxanes or antimetabolites [127]. Also, tissue
penetration of IP chemotherapy is very limited compared to
systemic treatment, and therefore tumors with a volume larger
than a few millimeters will be not be adequately exposed [32].
Also, the beneficial anticancer and immune effects of IP
hyperthermia remain to be confirmed in the clinical setting.
Nevertheless, there remains a solid rationale to further develop
IP drug delivery for patients with PM, for whom few other effective
treatments are available. Several opportunities may allow to rede-
fine the value of IP drug delivery in the near future. First, we should
establish a thorough understanding of the tumor microenviron-
ment of PM and of the peritoneal ecosystem, and how it is affected
by current treatment strategies, specifically in colorectal cancer.
Second, the therapeutic index of IP chemotherapy should be
increased by developing compounds and platforms that allow
prolonged, metronomic exposure of the peritoneal surfaces at risk
without the requirement of an indwelling catheter. Recent rapid
advances in nanomedicine, biomaterials, and tissue engineering
hold great promise in this regard, and examples include IP thermo-
sensitive or pH sensitive gels, depots, and scaffolds [111,128]. The
introduction of intraperitoneal aerosol chemotherapy during
laparoscopy (PIPAC) has opened novel treatment opportunities in
patients with advanced, unresectable PM [62]. Third, the potential
should be further explored to combine IP chemotherapy with
stromal targeting, such as immune modulation or therapies direc-
ted at the extracellular matrix to enhance its hydraulic and diffusive
permeability, and thus enhance drug transport [32]. Finally, the
results of ongoing randomized trials are awaited in order to inform
clinical practice in patients with PM.
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